At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the Champalimaud Clinical Center, Lisbon, Portugal, discusses abstracts presented at the conference, including results from the EPHOS-B trial, which was designed to evaluate lapatinib and trastuzumab, alone and in combination, for early HER2-positive breast cancer; and results from the EORTC 10085/TBCRC/BIG/NABG International Male Breast Cancer Program, which was designed to understand pathologic prognostic factors of male breast cancer.
Allergy & Immunology
